Despite the involvement of a vast variety of pro-inflammatory mediators, exclusive blockage of TNF seems to result in better clinical outcomes in a broad range of diseases associated with inflammation and autoimmunity and clinical trials assessing TNF inhibitors for treatment of ARDS in severe COVID-19 patients have been proposed (Feldmann et al., 2020). This evidence concerns the gene TNF and acute respiratory distress syndrome.